Mainz Biomed (NASDAQ:QUCY) Upgraded at Wall Street Zen

Mainz Biomed (NASDAQ:QUCY) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also recently weighed in on QUCY. Maxim Group cut shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Weiss Ratings upgraded shares of Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 11th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mainz Biomed currently has a consensus rating of “Reduce”.

Mainz Biomed Trading Down 5.6%

Shares of QUCY opened at $2.20 on Friday. The stock has a market capitalization of $32.25 million, a PE ratio of -0.05 and a beta of 2.22. Mainz Biomed has a fifty-two week low of $0.30 and a fifty-two week high of $4.93. The business has a 50-day simple moving average of $1.31.

Mainz Biomed (NASDAQ:QUCY) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.13 million for the quarter.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.